Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="de Grève, Jacques" or (type any "bookEditor issueEditor" and editor="de Grève, Jacques")

Add to list
- Conference Paper
- C3
A comparison of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT with [18F]FDG-PET/CT in breast carcinoma patients

Odrade Gondry, Catarina Xavier, Johannes Heemskerk, Laurens Albert J Raes, Jens Debacker (UGent) , Frank De Geeter, Christel Fontaine, Marian Vanhoeij, SANDRINE ASPESLAGH (UGent) , Sofie Joris, et al.

(2023) EMIM 2023, European Molecular Imaging Meeting, Abstracts.
Add to list
Standard of care in 2021 for patients with ovarian cancer in Belgium

Ignace Vergote, Hannelore Denys (UGent) , Jacques De Grève, Christine Gennigens, Koen Van de Vijver (UGent) , Joseph Kerger, Peter Vuylsteke and Jean-Francois Baurain

(2021) BELGIAN JOURNAL OF MEDICAL ONCOLOGY. 15(6). p.286-291
Add to list
- Journal Article
- A1
- open access
Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer

Philippe Giron, Carolien Eggermont, Amir Noeparast, Hugo Vandenplas, Erik Teugels, Ramses Forsyth (UGent) , Olivier De Wever (UGent) , Pedro Aza‐Blanc, Gustavo J. Gutierrez and Jacques De Grève

(2021) INTERNATIONAL JOURNAL OF CANCER. 148(10). p.2579-2593
Add to list
- Journal Article
- A2
- open access
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer

Alfiah Noor, Ijeoma Adaku Umelo, Peter Kronenberger, Philipe Giron, Elly De Vlieghere (UGent) , Olivier De Wever (UGent) , Erik Teugels and Jacques De Grève

(2018) ONCOTARGET. 9(47). p.28731-28744
Add to list
Pharmacokinetic effects and safety of olaparib administered with endocrine therapy : a phase I study in patients with advanced solid tumours

Ruth Plummer, Henk M. Verheul, Filip Y. F. L. De Vos, Karin Leunen, L. Rhoda Molife, Christian Rolfo, Peter Grundtvig-Sørensen, Jacques De Grève, Sylvie Rottey (UGent) , Guy Jerusalem, et al.

(2018) ADVANCES IN THERAPY. 35(11). p.1945-1964
Add to list
- Journal Article
- A1
- open access
Breast cancer risk is increased in the years following false-positive breast cancer screening

Mathijs C Goossens, Isabel De Brabander, Jacques De Greve, Evelien Vaes, Chantal Van Ongeval, Koen Van Herck (UGent) and Eliane Kellen

(2017) EUROPEAN JOURNAL OF CANCER PREVENTION. 26(5). p.396-403
Add to list
- Journal Article
- A1
- open access
Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation : a multicenter academic phase II study in Caucasian patients (FIELT)

Jacques De Grève, Jan Van Meerbeeck (UGent) , Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, et al.

(2016) PLOS ONE. 11(3).
Add to list
- Journal Article
- A1
- open access
The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation : efficacy and safety

Erica Sermijn, Liesbeth Delesie (UGent) , Ellen Deschepper (UGent) , Ingrid Pauwels, Maryse Bonduelle, Erik Teugels and Jacques De Greve

(2016) FAMILIAL CANCER. 15(2). p.155-162
Add to list
- Journal Article
- A1
- open access
Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma

Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Chloé Ackaert, Marian Vanhoeij, Francois Duhoux, Thierry Gevaert, Philippe Simon, et al.

(2016) JOURNAL OF NUCLEAR MEDICINE. 57(1). p.27-33
Add to list
Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells

Ijeoma Adaku Umelo, Olivier De Wever (UGent) , Peter Kronenberger, Alfiah Noor, Erik Teugels, Gang Chen, Marc Bracke (UGent) and Jacques De Grève

(2015) LUNG CANCER. 90(2). p.167-174

Academic Bibliography

A comparison of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT with [18F]FDG-PET/CT in breast carcinoma patients

Standard of care in 2021 for patients with ovarian cancer in Belgium

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer

Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer

Pharmacokinetic effects and safety of olaparib administered with endocrine therapy : a phase I study in patients with advanced solid tumours

Breast cancer risk is increased in the years following false-positive breast cancer screening

Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation : a multicenter academic phase II study in Caucasian patients (FIELT)

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation : efficacy and safety

Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma

Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells

Contents

Support

Contact